iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
- Annual recurring revenue increased by 15% year-over-year to $8.7 million.
- Full-year operating cash flow improved to ($5) million from ($12.8) million.
- Total revenues for Q4 2023 were $4.7 million, up 2% from the previous year.
- Gross profit margin % increased to 91% in Q4 2023 from 84% in the previous year.
- GAAP net loss from continuing operations improved to ($0.5) million in Q4 2023.
- iCAD's President and CEO, Dana Brown, emphasized progress towards the company's transformation plan.
- Cash and cash equivalents stood at $21.7 million as of December 31, 2023.
- The company believes it has sufficient cash resources to fund its current planned operations without the need for additional funding.
- Total revenues for full-year 2023 decreased by 13%.
- Non-GAAP adjusted EBITDA showed a loss of ($0.4) million in Q4 2023.
- Product revenue decreased by 21.3% year-over-year for the twelve months ended December 31, 2023.
Insights
The reported Annual Recurring Revenue (ARR) growth of 15% year-over-year for iCAD Inc. is a positive indicator of the company's ability to retain and potentially expand its customer base over time. ARR is a critical metric for companies with a subscription-based revenue model as it provides a more predictable and stable revenue stream. The increase in ARR, coupled with the improvement in operating cash flow from ($12.8) million to ($5) million, suggests that iCAD is moving towards operational efficiency and better cash management.
However, the full-year revenue decline of 13% raises concerns about the company's market position and competitive dynamics. While the gross profit margin remains consistent at 85%, indicating stable production costs relative to sales, the drop in product revenue by 21.3% could reflect either a decrease in demand or increased competition. Investors should monitor subsequent quarters to determine if this is an ongoing trend or a one-time fluctuation.
The improvement in GAAP Net Loss from continuing operations suggests that the company's cost-cutting measures or operational adjustments are having a positive effect on the bottom line. However, a continuous net loss indicates that the company has not yet reached profitability, which is an essential factor for long-term sustainability.
From a market perspective, iCAD's focus on AI-powered solutions for cancer detection positions the company within a high-growth sector. The healthcare industry's increasing adoption of AI technologies for diagnostic accuracy and efficiency could serve as a tailwind for iCAD's offerings. The reported reading of over 40 million mammograms, with nearly 30% being tomosynthesis, demonstrates the company's significant footprint in the diagnostic imaging market.
The gross profit margin of 91% in Q4, up from 84%, is particularly noteworthy as it suggests a strong value proposition and pricing power for iCAD's products and services. However, it is essential to juxtapose this against the overall revenue decline to assess the company's market strategy effectiveness.
Given the company's statement about a three-phased transformation plan and investment in growth initiatives, stakeholders should look for signs of innovation and market expansion in future reports. The ability of iCAD to capitalize on its patient-centric mission and leverage its technological advancements will be crucial for its continued growth and market share acquisition.
Within the medical technology sector, iCAD's focus on early cancer detection through AI is a strategic advantage. The high gross profit margins indicate that iCAD's products have substantial intellectual property value and require a lower cost of goods sold relative to their selling price. This is often the case with software and technology-driven solutions, which can scale effectively once developed.
The issuance of 1,057,814 shares in at-the-market (ATM) offerings and the sale of Xoft resulting in net cash proceeds of $4.5 million reflect strategic financial moves to bolster the company's cash position. The management's confidence in funding current operations without additional fundraising is a positive signal to investors about the company's financial strategy and liquidity status.
For stakeholders, the key will be to monitor how effectively iCAD can translate its technological capabilities into commercial success. The company's ability to drive adoption of its AI-powered solutions in a competitive healthcare market will be critical. Future regulatory approvals and clinical trial outcomes will also play a significant role in shaping the company's trajectory.
Annual Recurring Revenue of
Full-Year Operating Cash Flow (
Year ending cash balance of
NASHUA, N.H., March 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, today announced results for its fiscal fourth quarter and full year ended December 31, 2023, as compared to the corresponding period of the last fiscal year.
Fourth Quarter 2023 Financial Highlights:
- Total ARR was
$8.7 million, up15% - Total revenues were
$4.7 million, up2% - Gross Profit Margin % was
91% , up from84% - GAAP Net Loss from continuing operations (
$0.5) million, improvement from ($2.3) million - Operating cash flow was (
$1.5) million, improvement from ($3.1) million
Full Year 2023 Financial Highlights:
- Total revenues were
$17.3 million, down13% - Gross Profit Margin % was
85% , flat year-over-year - GAAP Net Loss from continuing operations (
$7) million, improvement from ($9.9) million - Operating cash flow was (
$5) million, improvement from ($12.8) million
“Reflecting on solid Q4 results, iCAD has demonstrated strong execution and progress towards our three-phased transformation plan - realigning our base, strengthening our foundation, and investing in growth initiatives – allowing us to drive towards our patient-centric mission of creating a world where cancer can’t hide,” said Dana Brown, President and CEO, iCAD. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, of which nearly
Three Months Ended December 31, 2023 Financial Results
Total revenue for the fourth quarter of 2023 was
| (in 000’s) | Three months ended December 31, | ||||||||||||||
| 2023 | 2022 | $ Change | % Change | ||||||||||||
| Product revenue | $ | 2,970 | $ | 2,754 | $ | 216 | 7.8 | % | |||||||
| Service and supplies revenue | 1,771 | 1,881 | (110 | ) | -5.8 | % | |||||||||
| Total revenue | $ | 4,741 | $ | 4,635 | $ | 106 | 2.3 | % | |||||||
Gross Profit: Gross profit for the fourth quarter of 2023 was
Operating Expenses: Total operating expenses for the fourth quarter of 2023 were
GAAP Net Loss from continuing operations: Net loss from continuing operations for the fourth quarter of 2023 was (
Non-GAAP Adjusted Net Loss from continuing operations: Non-GAAP Adjusted Net Loss from continuing operations, a non-GAAP financial measure as defined below, for the fourth quarter of 2023 was (
Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA, a non-GAAP financial measure as defined below, for the fourth quarter of 2023 was a loss of (
Twelve Months Ended December 31, 2023 Financial Results
Total revenue for the twelve months ended December 31, 2023 was
| (in 000’s) | Twelve months ended December 31, | ||||||||||||||
| 2023 | 2022 | $ Change | % Change | ||||||||||||
| Product revenue | $ | 9,930 | $ | 12,620 | $ | (2,690 | ) | -21.3 | % | ||||||
| Service and supplies revenue | 7,388 | 7,182 | 206 | 2.9 | % | ||||||||||
| Total revenue | $ | 17,318 | $ | 19,802 | $ | (2,484 | ) | -12.5 | % | ||||||
Gross Profit: Gross profit for the twelve months ended December 31, 2023 was
Operating Expenses: Total operating expenses for the twelve months ended December 31, 2023 were
GAAP Net Loss from continuing operations: Net loss from continuing operations for the twelve months ended December 31, 2023 was (
Non-GAAP Adjusted Net Loss from continuing operations: Non-GAAP Adjusted Net Loss from continuing operations, a non-GAAP financial measure as defined below, for the twelve months ended December 31, 2023 was (
Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA, a non-GAAP financial measure as defined below, for the first twelve months of 2023 was a loss of (
Cash and cash equivalents: Cash and cash equivalents were
Conference Call:
A conference call will be held today, Tuesday, March 12, 2024 at 4:30 PM ET.
- Toll Free: 888-506-0062
- International: 973-528-0011
- Participant Access Code: 402294
- Webcast: https://www.webcaster4.com/Webcast/Page/2879/49733
Use of Non-GAAP Financial Measures
In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. When analyzing the Company’s operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP. The Company’s quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company’s website at www.icadmed.com
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
Media inquiries: pr@icadmed.com
Investor Inquiries: ir@icadmed.com
| iCAD, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except for share data) (Unaudited) | |||||||
| December 31, | December 31, | ||||||
| 2023 | 2022 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 21,670 | $ | 21,313 | |||
| Trade accounts receivable, net of allowance for credit losses of | 6,549 | 5,769 | |||||
| Inventory, net | 917 | 2,054 | |||||
| Prepaid expenses and other current assets | 699 | 1,571 | |||||
| Current assets held for sale | — | 7,534 | |||||
| Total current assets | $ | 29,835 | $ | 38,241 | |||
| Property and equipment, net of accumulated depreciation of | 1,823 | 704 | |||||
| Operating lease assets | 461 | 670 | |||||
| Other assets | 692 | 19 | |||||
| Intangible assets, net of accumulated amortization of | 148 | 264 | |||||
| Goodwill | 8,362 | 8,362 | |||||
| Deferred tax assets | 97 | 116 | |||||
| Noncurrent assets held for sale | — | 3,329 | |||||
| Total assets | $ | 41,418 | $ | 51,705 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 712 | $ | 1,446 | |||
| Accrued and other expenses | 2,448 | 2,541 | |||||
| Lease payable—current portion | 188 | 217 | |||||
| Deferred revenue—current portion | 3,400 | 3,653 | |||||
| Current held for sale | — | 5,595 | |||||
| Total current liabilities | 6,748 | 13,452 | |||||
| Lease payable, net of current | 273 | 455 | |||||
| Deferred revenue, net of current | 974 | 393 | |||||
| Deferred tax | 6 | 6 | |||||
| Noncurrent liabilities held for sale | — | 2,497 | |||||
| Total liabilities | 8,001 | 16,803 | |||||
| Commitments and Contingencies | |||||||
| Stockholders’ equity: | |||||||
| Preferred stock, | — | — | |||||
| Common stock, | 265 | 254 | |||||
| Additional paid-in capital | 306,250 | 302,899 | |||||
| Accumulated deficit | (271,683 | ) | (266,836 | ) | |||
| Treasury stock at cost, 185,831 shares as of both December 31, 2023 and December 31, 2022 | (1,415 | ) | (1,415 | ) | |||
| Total stockholders’ equity | 33,417 | 34,902 | |||||
| Total liabilities and stockholders’ equity | $ | 41,418 | $ | 51,705 | |||
| iCAD, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (In thousands, except for per share data) (Unaudited) | |||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenue: | |||||||||||||||
| Products | $ | 2,970 | $ | 2,754 | $ | 9,930 | $ | 12,620 | |||||||
| Services | 1,771 | 1,881 | 7,388 | 7,182 | |||||||||||
| Total revenue | 4,741 | 4,635 | 17,318 | 19,802 | |||||||||||
| Cost of revenue: | |||||||||||||||
| Products | 287 | 405 | 1,387 | 1,658 | |||||||||||
| Services | 109 | 301 | 1,060 | 1,217 | |||||||||||
| Amortization and depreciation | 22 | 27 | 86 | 108 | |||||||||||
| Total cost of revenue | 418 | 733 | 2,533 | 2,983 | |||||||||||
| Gross profit | 4,323 | 3,902 | 14,785 | 16,819 | |||||||||||
| Operating expenses: | |||||||||||||||
| Engineering and product development | 1,252 | 1,134 | 5,161 | 5,493 | |||||||||||
| Marketing and sales | 2,049 | 2,584 | 7,740 | 10,790 | |||||||||||
| General and administrative | 1,675 | 2,713 | 9,324 | 10,517 | |||||||||||
| Amortization and depreciation | 63 | 48 | 249 | 217 | |||||||||||
| Total operating expenses | 5,039 | 6,479 | 22,474 | 27,017 | |||||||||||
| Loss from operations | (716 | ) | (2,577 | ) | (7,689 | ) | (10,198 | ) | |||||||
| Other income/ (expense): | |||||||||||||||
| Interest expense | (14 | ) | (2 | ) | (16 | ) | (10 | ) | |||||||
| Interest income | 201 | 124 | 729 | 213 | |||||||||||
| Other income (expense), net | (6 | ) | (14 | ) | (39 | ) | |||||||||
| Other income (expense), net | 181 | 122 | 699 | 164 | |||||||||||
| Loss before provision for income taxes | (535 | ) | (2,455 | ) | (6,990 | ) | (10,034 | ) | |||||||
| Benefit (Provision) for tax expense | (7 | ) | 116 | (20 | ) | 116 | |||||||||
| Loss from continuing operations | (542 | ) | (2,339 | ) | (7,010 | ) | (9,918 | ) | |||||||
| Income (loss) from discontinued operations | 1,904 | (756 | ) | 2,163 | (3,738 | ) | |||||||||
| Net loss and comprehensive loss | $ | 1,362 | $ | (3,095 | ) | $ | (4,847 | ) | $ | (13,656 | ) | ||||
| Net loss per share: | |||||||||||||||
| Loss from continuing operations, basic and diluted | $ | (0.02 | ) | $ | (0.09 | ) | $ | (0.27 | ) | $ | (0.39 | ) | |||
| Loss from discontinued operations, basic and diluted | $ | 0.07 | $ | (0.03 | ) | $ | 0.08 | $ | (0.15 | ) | |||||
| Net loss per share, basic and diluted | $ | 0.05 | $ | (0.12 | ) | $ | (0.19 | ) | $ | (0.54 | ) | ||||
| Weighted average number of shares used in computing loss per share: | 26,323 | 25,260 | 25,613 | 25,202 | |||||||||||
| iCAD, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) | |||||||
| For the Twelve Months ended | |||||||
| December 31, | |||||||
| 2023 | 2022 | ||||||
| Cash flow from operating activities: | |||||||
| Net loss | $ | (4,847 | ) | $ | (13,656 | ) | |
| Adjustments to reconcile net loss to net cash used for operating activities: | |||||||
| Gain on sale of business | (2,592 | ) | — | ||||
| Amortization | 170 | 211 | |||||
| Depreciation | 239 | 310 | |||||
| Non-cash lease expense | 487 | 708 | |||||
| Bad debt provision | 177 | 732 | |||||
| Stock-based compensation | 1,316 | 1,686 | |||||
| Deferred tax | 20 | (116 | ) | ||||
| Other, net | (1 | 9 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (1,751 | ) | (739 | ) | |||
| Inventory | 1,489 | (1,218 | ) | ||||
| Prepaid and other assets | 972 | 1,152 | |||||
| Accounts payable | (1,086 | ) | (806 | ) | |||
| Accrued and other expenses | (1,279 | ) | (961 | ) | |||
| Lease liabilities | (484 | ) | (767 | ) | |||
| Deferred revenue | 2,206 | 665 | |||||
| Total adjustments | (117 | ) | 866 | ||||
| Net cash used for operating activities | (4,964 | ) | (12,790 | ) | |||
| Cash flow from investing activities: | |||||||
| Proceeds from sale of business, net of transaction costs | 4,539 | — | |||||
| Additions to patents, technology and other | — | (10 | ) | ||||
| Additions to property and equipment | (942 | ) | (524 | ) | |||
| Capitalization of internal-use software | (342 | ) | — | ||||
| Net cash used for investing activities | 3,255 | (534 | ) | ||||
| Cash flow from financing activities: | |||||||
| Issuance of common stock for cash, net | 1,966 | — | |||||
| Issuance of common stock pursuant to Employee Stock Purchase Plan | — | 148 | |||||
| Issuance of common stock pursuant to stock option plans | 80 | 207 | |||||
| Net cash provided by financing activities | 2,046 | 355 | |||||
| (Decrease) increase in cash and cash equivalents | 337 | (12,969 | ) | ||||
| Cash and cash equivalents, beginning of period | 21,313 | 34,282 | |||||
| Cash and cash equivalents, end of period | $ | 21,650 | $ | 21,313 | |||
| Supplemental disclosure of cash flow information: | |||||||
| Interest paid | $ | 16 | $ | 9 | |||
| Amendment to right-of-use assets obtained in exchange for operating lease liabilities | $ | — | $ | 3,011 | |||
Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures and Definitions
The Company reports its financial results in accordance with United States generally accepted accounting principles, or GAAP. However, management believes that in order to understand the Company’s short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and/or impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in the Company’s ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of the Company’s ongoing business with prior periods more difficult, obscure trends in ongoing operations or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing the Company’s financial and operational performance and comparing this performance to its peers and competitors.
Management defines “Non-GAAP Adjusted EBITDA” as the sum of GAAP Net Loss before provisions for interest expense, other income, stock-based compensation expense, depreciation and amortization, tax expense, severance, gain on sale of assets, loss on disposal of assets, acquisition and litigation related expenses. Management considers this non-GAAP financial measure to be an indicator of the Company’s operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company’s overall financial performance.
The non-GAAP financial measures do not replace the presentation of the Company’s GAAP financial results and should only be used as a supplement to, not as a substitute for, the Company’s financial results presented in accordance with GAAP. The Company has provided a reconciliation of each non-GAAP financial measure used in its financial reporting and investor presentations to the most directly comparable GAAP financial measure.
Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:
- Interest expense: The Company excludes interest expense which includes interest from the facility agreement, interest on capital leases and interest on the convertible debentures from its non-GAAP Adjusted EBITDA calculation.
- Stock-based compensation expense: excluded as these are non-cash expenses that management does not consider part of ongoing operating results when assessing the performance of the Company’s business, and also because the total amount of expense is partially outside of the Company’s control as it is based on factors such as stock price volatility and interest rates, which may be unrelated to our performance during the period in which the expense is incurred.
- Amortization and Depreciation: Purchased assets and intangibles are amortized over a period of several years and generally cannot be changed or influenced by management after they are acquired. Accordingly, these non-cash items are not considered by management in making operating decisions, and management believes that such expenses do not have a direct correlation to future business operations. Thus, including such charges does not accurately reflect the performance of the Company’s ongoing operations for the period in which such charges are incurred.
- Severance and Furlough: The Company has incurred severance and furlough expenses in connection with restructuring and in connection with the separation of its former CEO. The Company excludes these items from its non-GAAP financial measures when evaluating its continuing business performance as such items can vary significantly and do not reflect expected future operating expenses. In addition, management believes that such items do not have a direct correlation to future business operations.
- Loss on fair value of convertible debentures. The Company excludes this non-cash item as it is not considered by management in making operating decisions, and management believes that such item does not have a direct correlation to future business operations.
- Litigation related: These expenses consist primarily of settlement, legal and other professional fees related to litigation. The Company excludes these costs from its non-GAAP measures primarily because the Company believes that these costs have no direct correlation to the core operations of the Company.
- Loss on extinguishment of debt: The Company excludes this non-cash item as it is not considered by management in making operating decisions, and management believes that such item does not have a direct correlation to future business operations.
On occasion in the future, there may be other items, such as loss on extinguishment of debt, significant asset impairments, restructuring charges or significant gains or losses from contingencies that the Company may exclude if it believes that doing so is consistent with the goal of providing useful information to investors and management.
Definitions
Starting in the third quarter of 2023, the Company began reporting Annual Recurring Revenue (“ARR”) with each quarterly earnings announcement. The Company’s management believes this is a useful metric for purposes of assessing progress in transitioning to a subscription-based business model. ARR should be viewed independently of revenue and does not represent our revenue under U.S. GAAP on an annualized basis, as it is an operating metric that can be impacted by contract start dates, end dates, cancellations, and renewal rates. Subscription ARR is not intended to be a replacement for forecasts of revenue. The following are the variations of ARR the Company intends to present:
- Total ARR (T-ARR) represents the annualized value of subscription license, maintenance contracts and active cloud services at the end of a reporting period.
- Maintenance Services ARR (M-ARR) represents the annualized value of active perpetual license maintenance service contracts at the end of the reporting period.
- Subscription ARR (S-ARR) represents the annualized value of active subscription or term licenses at the end of a reporting period.
- Cloud ARR (C-ARR) represents the annualized value of active cloud services contracts at the end of a reporting period.
| Non-GAAP Adjusted EBITDA Set forth below is a reconciliation of the Company’s “Non-GAAP Adjusted EBITDA” (Unaudited) (In thousands except for per share data) | |||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| GAAP Net Loss from continuing operations | $ | (542 | ) | $ | (2,339 | ) | $ | (7,010 | ) | $ | (9,918 | ) | |||
| Interest expense | 14 | 2 | 16 | 10 | |||||||||||
| Interest income | (201 | ) | (124 | ) | (729 | ) | (213 | ) | |||||||
| Other expense | 6 | — | 14 | 39 | |||||||||||
| Stock compensation | 202 | 317 | 1,316 | 1,686 | |||||||||||
| Depreciation & amortization | 85 | 75 | 335 | 325 | |||||||||||
| Severance and Furlough | — | 100 | 178 | 100 | |||||||||||
| Tax expense | 7 | (116 | ) | 20 | (116 | ) | |||||||||
| Non-GAAP Adjusted EBITDA | $ | (429 | ) | $ | (2,085 | ) | $ | (5,860 | ) | $ | (8,087 | ) | |||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| GAAP Net Loss from continuing operations | $ | (542 | ) | $ | (2,339 | ) | $ | (7,010 | ) | $ | (9,918 | ) | |||
| Adjustments to Net Loss: | |||||||||||||||
| Severance and Furlough | — | 100 | 178 | 100 | |||||||||||
| Non-GAAP Adjusted Net Loss from continuing operations | $ | (542 | ) | $ | (2,239 | ) | $ | (6,832 | ) | $ | (9,818 | ) | |||
| Net Loss per share from continuing operations —basic and diluted | |||||||||||||||
| GAAP Loss from continuing operations, basic and diluted | $ | (0.02 | ) | $ | (0.09 | ) | $ | (0.27 | ) | $ | (0.39 | ) | |||
| Adjustments to Net Loss (as detailed above) | — | 0.00 | 0.01 | 0.00 | |||||||||||
| Non-GAAP Adjusted Loss per share from continuing operations | $ | (0.02 | ) | $ | (0.09 | ) | $ | (0.27 | ) | $ | (0.39 | ) | |||
FAQ
What was iCAD's annual recurring revenue for the fiscal year?
What was the change in total revenues for Q4 2023 compared to the previous year?
Who is the President and CEO of iCAD?
What was the gross profit margin % in Q4 2023?
What was the GAAP net loss from continuing operations in Q4 2023?
